Apothecary Pharma has initiated a voluntary recall of 23 vials of injectable drugs distributed nationwide due to sterility assurance concerns, according to the Food and Drug Administration [1]. The recall, classified as Class II on October 8, 2025, includes 22 vials of compounded tirzepatide—a GLP-1 medication containing the same active ingredient as Eli Lilly's Mounjaro and Zepbound—and one vial of NAD+ injection [1]. The affected tirzepatide product is an 18 mg/mL prescription injection in a 4 mL multidose vial (NDC 85091-001-18), with recalled lots ranging from AP-202622 through AP-202625 and AP-202627 through AP-202644, with beyond-use dates spanning October 7 through November 26, 2026 [1].
The recall follows a December 2025 FDA warning letter to Apothecary Pharma citing serious deficiencies in the North Carolina company's sterile drug production practices, though the FDA has not established a direct connection between those findings and the current recall [1]. Apothecary Pharma initiated the recall on September 24 and notified recipients by letter, with the recall remaining ongoing [1]. Notably, the FDA notice did not identify any reported illnesses or injuries linked to the recall, and the Class II classification indicates that serious health consequences are considered unlikely [1]. Consumers are advised to check their vials or pharmacy records, stop using affected products, and contact their pharmacist or prescriber for guidance, with medical attention recommended if experiencing fever, redness, swelling, or worsening pain after an affected injection [1].
CONCLUSION
While the recall of compounded tirzepatide vials presents a localized supply disruption, the Class II classification and absence of reported injuries suggest limited immediate patient safety impact. The recall is unlikely to materially affect Eli Lilly's GLP-1 market position, as the affected products are compounded alternatives rather than branded Mounjaro or Zepbound formulations.